Scinai Immunotherapeutics (SCNI) Gains from Investment Securities (2023 - 2026)
Scinai Immunotherapeutics (SCNI) reported Gains from Investment Securities of $3.6 million for Q1 2026, up 329.74% on a YoY basis from $832370.2 in Q1 2025, and up 329.74% sequentially from -$1.6 million in Q1 2025.
Scinai Immunotherapeutics (SCNI) Gains from Investment Securities (2023 - 2026) Analysis & Trends
Scinai Immunotherapeutics (SCNI) has 4 years of Gains from Investment Securities data on file, last reported at $3.6 million in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities rose 329.74% year-over-year to $3.6 million; the trailing twelve-month figure through Mar 2026 stood at $2.0 million (up 229.99% YoY), and the FY2025 full-year result was -$3000.0, up 96.77% from the prior year.
- Gains from Investment Securities climbed to $3.6 million in Q1 2026, from -$1.6 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $3.6 million in Q1 2026 to a low of -$2.6 million in Q1 2023.
- A 4-year average of -$276625.0 and a median of -$403500.0 in 2023 frame the typical range for Gains from Investment Securities.
- Across the five-year window, Gains from Investment Securities slumped 1521.88% in 2025 and jumped 329.74% in 2026, its largest moves.
- Tracing SCNI's Gains from Investment Securities over 4 years: stood at -$216000.0 in 2023, then soared by 101.39% to $3000.0 in 2024, then tumbled by 52000.0% to -$1.6 million in 2025, then jumped by 329.74% to $3.6 million in 2026.
- Business Quant data shows SCNI's Gains from Investment Securities at $3.6 million in Q1 2026, -$1.6 million in Q1 2025, and $3000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Scinai Immunotherapeutics | 3.74 Bn | 624.08 Mn | -1.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.58 Mn |
| Mar 31, 2026 | 3.58 Mn |
| Mar 31, 2025 | -1.56 Mn |
| Mar 31, 2025 | -1.56 Mn |
| Jun 30, 2024 | 3,000.00 |
| Jun 30, 2024 | 3,000.00 |
| Mar 31, 2024 | -96,000.00 |
| Mar 31, 2024 | -96,000.00 |
| Dec 31, 2023 | -216,000.00 |
| Dec 31, 2023 | -216,000.00 |
| Sep 30, 2023 | -591,000.00 |
| Sep 30, 2023 | -591,000.00 |
| Jun 30, 2023 | -765,000.00 |
| Jun 30, 2023 | -765,000.00 |
| Mar 31, 2023 | -2.57 Mn |
| Mar 31, 2023 | -2.57 Mn |